PANRETIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PANRETIN (PANRETIN).
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
| Metabolism | Metabolized primarily by CYP2C9, CYP3A4, and CYP2C8 to major metabolites (e.g., 4-oxo-alitretinoin, 9-cis-retinoic acid). Glucuronidation also contributes. |
| Excretion | Primarily hepatic metabolism; less than 1% excreted unchanged in urine. |
| Half-life | Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application. |
| Protein binding | >99% bound to plasma proteins, primarily albumin and lipoproteins. |
| Volume of Distribution | Not applicable for topical administration; systemic absorption is minimal with no established Vd. |
| Bioavailability | Systemic bioavailability after topical application is <1% of applied dose. |
| Onset of Action | Clinical improvement in cutaneous Kaposi sarcoma lesions typically seen within 2-4 weeks of twice-daily topical application. |
| Duration of Action | Duration of effect is continuous with regular application; response is sustained with continued use. |
| Molecular Weight | 300.44 |
Apply 0.1% gel topically to lesions twice daily.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment recommended for hepatic impairment. |
| Pediatric use | Not indicated for pediatric patients below 18 years of age. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for increased skin sensitivity. |
| 1st trimester | Contraindicated due to teratogenicity; risk of major congenital malformations (CNS, cardiovascular, facial) and spontaneous abortion. |
| 2nd trimester | Contraindicated; continued teratogenic risk; avoid use unless no alternative. |
| 3rd trimester | Contraindicated; fetal harm potential; safer alternatives recommended. |
Clinical note
Comprehensive clinical and safety monograph for PANRETIN (PANRETIN).
| Placental transfer | Alitretinoin crosses the placenta in animal studies; human data demonstrate measurable fetal concentrations. Degree of transfer is significant, contributing to teratogenicity. |
| Breastfeeding | Panretin (alitretinoin) is a retinoid; minimal excretion into breast milk is expected due to high protein binding and molecular weight. However, due to potential adverse effects in the infant (e.g., retinoid toxicity), breastfeeding is generally not recommended during treatment and for at least 1 month after last dose. |
■ FDA Black Box Warning
Not applicable for topical formulation. Oral alitretinoin (not marketed in US) carries a boxed warning for teratogenicity and must not be used during pregnancy.
| Serious Effects |
PregnancyWomen of childbearing potential not using effective contraceptionHypersensitivity to alitretinoin or excipients
| Precautions | Teratogenicity: Avoid use during pregnancy; effective contraception required, Photosensitivity: Avoid excessive sun exposure, Local skin reactions: erythema, edema, peeling at application site, Hyperlipidemia: Monitor lipids in prolonged use, Pancreatitis: Risk in patients with hypertriglyceridemia, Hepatotoxicity: Monitor liver function tests, Pseudotumor cerebri: Discontinue if signs of intracranial hypertension |
| Food/Dietary | No known food interactions. Avoid concurrent use of other topical products on the same area. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnormalities). First trimester exposure carries highest risk. Second and third trimester: risk of fetal retinoid syndrome (craniofacial dysmorphism, CNS anomalies, cardiovascular malformations). Effective contraception must be used. |
| Fetal Monitoring | Pregnancy test within 1 week prior to therapy, monthly during treatment, and 4-6 weeks after discontinuation. Monitor for signs of retinoid toxicity (headache, visual disturbances, pseudotumor cerebri). Fetal ultrasound for anomalies if exposure occurs. |
| Fertility Effects | No specific human data; no known adverse effects on fertility from systemic absorption (topical use). However, retinoids may cause reversible menstrual irregularities. Male fertility: no significant effects reported. |
| Clinical Pearls | Panretin (alitretinoin) gel is a topical retinoid indicated for cutaneous Kaposi sarcoma. Use gloves during application; avoid application to normal skin as it may cause irritation. Monitor for local adverse reactions like erythema, edema, and pain. Do not use concurrently with other topical agents on the same site. |
| Patient Advice | Apply a thin layer only to Kaposi sarcoma lesions, avoiding healthy skin. · Wash hands thoroughly before and after application. · Do not cover with bandages or dressings unless instructed. · Expected side effects include redness, swelling, and pain at application site. · Avoid exposure to sunlight or tanning lamps; use sunscreen on treated areas. · Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. |